In summary, targeting the CXCL1–CXCR2 axis holds significant promise for future cancer therapies, and focusing on CXCR2 allows for a more comprehensive disruption of tumor-promoting signaling pathways, as well as direct translational applicability. The gene discussed is CXCR2; the disease is neoplasm.